Dimethaid Research Inc. recently announced that it has received an approvable letter from Health Canada for PENNSAID®, a topical solution for treating the symptoms of osteoarthritis (OA) of the knee – pain, stiffness and impaired physical function, by utilizing its patented transcellular technology.
“Dimethaid developed this treatment with the goal of improving the quality of life for millions of Canadians,” said Rebecca Keeler, President and CEO, Dimethaid Research Inc. “We are extremely pleased that PENNSAID, which was developed in Canada and is being manufactured at our facility in Quebec, will soon be available across Canada to people suffering from osteoarthritis. With today’s announcement, our vision has come a significant step closer to reality.”
Currently more than three million Canadians suffer from OA, and the number is expected to increase as the population ages. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen are commonly used to relieve OA pain and are traditionally taken as oral medication. Oral NSAIDs have been linked to serious side effects, including gastrointestinal, kidney and liver abnormalities. According to the Arthritis Society, an estimated 1,900 Canadians die from NSAID-induced ulcers, every year. PENNSAID is designed to minimize these problems.
PENNSAID is an alternative to oral NSAIDs, and is different from conventional transdermal products designed to provide sustained drug levels within the bloodstream. After being applied to the skin, these drugs – usually patches or gels – spread throughout the body. By taking this path, these older topicals act the same as oral medication, making them less than ideal for treating localized conditions.
PENNSAID has also been approved in the UK and a number of European countries, and it is currently under review by the Food and Drug Administration in the United States.